-+ 0.00%
-+ 0.00%
-+ 0.00%

Sionna Therapeutics Presents Preclinical Data That Shows NBD1 Stabilizers, In Dual Combinations With Proprietary Complementary Modulators, Enable Full CFTR Correction In CF Models

Benzinga·06/06/2025 15:03:41
Listen to the news

Data featured in oral presentation and poster session at 48th European Cystic Fibrosis Conference

WALTHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the presentation of preclinical data that demonstrate that the company's nucleotide-binding domain 1 (NBD1) stabilizers, in dual combinations with proprietary complementary modulators, enable full CFTR correction in CF models. The data are featured in an oral presentation and poster session at the European Cystic Fibrosis Society (ECFS) 48th European Cystic Fibrosis Conference being held in Milan, Italy.